| Karen Lyzette Piazza, | |
|
21 Calle San Joaquin, Adjuntas, PR 00601-2254 | |
| (787) 829-2480 | |
| Not Available |
| Full Name | Karen Lyzette Piazza |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 21 Calle San Joaquin, Adjuntas, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477133825 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 6475 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karen Lyzette Piazza, Po Box 669, Adjuntas, PR 00601-0669 Ph: () - | Karen Lyzette Piazza, 21 Calle San Joaquin, Adjuntas, PR 00601-2254 Ph: (787) 829-2480 |
News Archive
Burn specialists at Massachusetts General Hospital announced today they have successfully used live-cell, genetically engineered pig skin (xenograft) for the temporary closure of a burn wound.
"Health care stocks lagged the broader market's recovery in 2009," Forbes reports.
The Minister for Health and Children Mr. Micheal Martin, T.D. has announced that €5m is being made available for research in Ireland in the area of autism over the next five years.
The Center for Global Health Policy's "Science Speaks" blog summarizes an event held Thursday, titled "AIDS-free Generation? Not Without Women," that was sponsored by the National Council of Women's Organizations. The session aimed "to draw attention to pivotal issues surrounding the impact of AIDS on women worldwide" ahead of the International AIDS Conference, the blog states.
Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.
› Verified 8 days ago
Mrs. Nelida Velez, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 36 Bartolomei, Urb. San Joaquin, Adjuntas, PR 00601 Phone: 787-829-2907 | |
Mrs. Jenilsa Velez, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 21 Calle San Joaquin, Adjuntas, PR 00601 Phone: 787-829-2480 Fax: 787-829-6000 | |
Ivette Ramos Gonzalez, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle Munoz Rivera, #26, Adjuntas, PR 00601 Phone: 787-829-2495 Fax: 787-829-2495 | |
Anibal Rodriguez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 22 Calle Barbosa, Adjuntas, PR 00601 Phone: 787-829-3305 Fax: 787-829-7187 | |
Mrs. Nivia Mercado, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 22 Calle Barbosa, Adjuntas, PR 00601 Phone: 787-829-3305 Fax: 787-829-7187 | |
Dr. Frances Ortiz, PHARM.D, M.B.A., CPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 22 Calle Barbosa, Adjuntas, PR 00601 Phone: 787-829-3305 Fax: 787-836-7243 |